Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive crawled date : 2021 - 11 - 30 save search
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ATRA | $0.6755 -2.34% -2.4% 1.6M
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
treatment ema europe application therapeutics disease positive iot
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
Blade Therapeutics Announces Positive Topline Data from Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis
Published: 2021-11-30 (Crawled : 14:00) - biospace.com/
BIOT | $10.15 -0.78% -0.2% 44K
|
|
| O: -0.1%
H: 0.3%
C: 0.3%
fibrosis xin therapeutics phase 1 positive topline cudetaxestat
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian Cancer
Published: 2021-11-30 (Crawled : 13:00) - globenewswire.com
ZLAB | $14.08 -0.99% -0.99% 470K
|
Health Technology
|
| O: -7.63%
H: 0.0%
C: 0.0%
chinese treatment positive therapy women results cancer topline phase 3 ovarian cancer primec
Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Program
Published: 2021-11-30 (Crawled : 13:00) - biospace.com/
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: 0.0%
disease positive results pre-clinical positive results preclinical
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Published: 2021-11-30 (Crawled : 12:30) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 39.31%
H: 0.0%
C: 0.0%
positive results cancer ovarian cancer trial mirvetuximab topline
First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections
Published: 2021-11-30 (Crawled : 12:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K
|
Manufacturing
|
| O: 42.63%
H: 0.0%
C: 0.0%
treatment biopharma test positive gastrointestinal trial covid infections
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In Vitro
Published: 2021-11-30 (Crawled : 07:00) - globenewswire.com
MOLN | News | $3.74 -3.54% 6.2K
|
Professional, Scientific, and T...
|
| O: 15.09%
H: 7.56%
C: 3.78%
molecular ensovibep xin sars-cov-2 positive in vitro
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
LYT | $4.22 4.72% 5.62% 1.4M
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
Your saved searches
Save your searches and get alerts when important news are released.